Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTK | P29376 | 2/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | MST1R | Q04912 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11075249 | 0.98 | LTK (0.49) | LTKALKDYRK1BRETMET | |
| SCHEMBL31397701 | 0.98 | LTK (0.49) | LTKALKDYRK1BRETMET | |
| SCHEMBL18126808 | 0.75 | ALDH1A1 (0.43) | ADORA3KDM4EHSD17B10ALDH1A1GLA | |
| SCHEMBL1818352 | 0.74 | RET (0.50) | LTKALKDYRK1BRETMET | |
| SCHEMBL11032723 | 0.73 | LTK (0.41) | LTKALKDYRK1BRETMET | |
| SCHEMBL3519674 | 0.72 | KDM4E (0.50) | ADORA3KDM4EHSD17B10ALDH1A1GLA | |
| SCHEMBL18632530 | 0.72 | SCN5A (0.62) | LTKALKDYRK1BRETMET | |
| SCHEMBL18632535 | 0.72 | SCN5A (0.62) | LTKALKDYRK1BRETMET | |
| SCHEMBL20772757 | 0.71 | PARP1 (0.42) | LTKALKDYRK1BRETMET | |
| SCHEMBL16439323 | 0.71 | CHEK1 (0.45) | LTKALKDYRK1BRETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | claimed |
| US-12221438-B2 | Continuous process for the preparation of trazodone | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2025-02-11 | — | — | US | claimed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | claimed |
| CN-117517545-A | Method for detecting trazodone hydrochloride related substances | 重庆锐恩医药有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-111886235-B | Continuous process for preparing trazodone | 方济各安吉利克化学联合股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | claimed |
| EP-3749668-B1 | CONTINUOUS PROCESS FOR THE PREPARATION OF TRAZODONE | ACRAF (IT) | 2022-04-06 | — | — | EP | claimed |
| US-20160332016-A1 | Fire Extinguishing Composition Comprising Aldoketones Compound | NANO FIRE, LLC | 2016-11-17 | — | — | US | claimed |
| EP-2606049-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | Albany Molecular Research, Inc. (US) | 2013-06-26 | — | — | EP | claimed |
| WO-2012024397-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-23 | — | — | WO | claimed |
| EP-0025985-B1 | 2-SUBSTITUTED TRIAZOLO(4,3-1)PYRIDIN-3(2H)-ONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DEPRESSION | Bristol-Myers Company (US) | 1983-11-23 | — | — | EP | claimed |
| EP-0025985-A1 | 2-Substituted triazolo(4,3-1)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions for the treatment of depression | Bristol-Myers Company (US) | 1981-04-01 | — | — | EP | claimed |
| US-4254124-A | 2-(3-(4-(TRIFLUOROMETHYLPHENYL)-PIPERAZINO)-PROPYL)-S-TRIAZOLO(4,3 -A)PYRIDIN-3-ONE | MEAD JOHNSON & COMPANY (US) | 1981-03-03 | — | — | US | claimed |
| US-20260146199-A1 | METHOD FOR PROCESSING SEMICONDUCTOR SUBSTRATE, METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE, AND PROCESSING SOLUTION FOR SEMICONDUCTOR DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260108508-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2026-04-23 | — | — | US | disclosed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-0025985-A1 | 2-Substituted triazolo(4,3-1)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions for the treatment of depression | Bristol-Myers Company (US) | 1981-04-01 | — | — | EP | disclosed |
| EP-0025985-A1 | 2-Substituted triazolo(4,3-1)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions for the treatment of depression | Bristol-Myers Company (US) | 1981-04-01 | — | — | EP | disclosed |
| EP-0025603-A1 | Triazolo (4,3-a)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions containing them | Bristol-Myers Company (US) | 1981-03-25 | — | — | EP | disclosed |
| US-4254124-A | 2-(3-(4-(TRIFLUOROMETHYLPHENYL)-PIPERAZINO)-PROPYL)-S-TRIAZOLO(4,3 -A)PYRIDIN-3-ONE | MEAD JOHNSON & COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221438-B2 | Continuous process for the preparation of trazodone | CYP3A5, OPRK1, OPRD1 | LTK 2853/4885ALK 2355/4885DYRK1B 1263/4885 |
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | LTK 4655/4885ALK 3913/4885DYRK1B 3837/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | LTK 743/4885ALK 1636/4885DYRK1B 3/4885 |
| US-20260146199-A1 | METHOD FOR PROCESSING SEMICONDUCTOR SUBSTRATE, METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE, AND PROCESSING SOLUTION FOR SEMICONDUCTOR DEVICE | AS3MT, ASH1L, HMOX2 | LTK 3530/4885ALK 1293/4885DYRK1B 970/4885 |
| US-20260108508-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | HTR1A, HTR3A, HTR2C | LTK 988/4885ALK 79/4885DYRK1B 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.